Bausch + Lomb Corp.’s stock soared 10% early Wednesday, after the vision-care company’s adjusted fourth-quarter profit topped estimates and it offered upbeat revenue guidance for 2024.
The Vaughan, Ontario-based company
BLCO,
had a net loss of $54 million, or 15 cents a share, for the quarter, after a loss of $1 million in the year-earlier period. Adjusted per-share earnings came to 24 cents, ahead of the 17-cent FactSet consensus.
Revenue rose to $1.173 billion from $996 million a year ago, also ahead of the $1.106 billion FactSet consensus.
Chief Executive Brent Saunders said revenue growth in 2023 exceeded the company’s expectations and has set the tone for 2024.
The company is now expecting 2024 revenue of $4.600 billion to $4.700 billion, while FactSet is expecting $4.550 billion.
See also: Bausch + Lomb to buy ‘dry eye’ treatment from Novartis in a $2.5 billion deal
Revenue at the company’s vision care segment rose 6% in the quarter to $662 million. Growth was driven by higher sales of Lumify eye drops, Eye Vitamins and Dry Eye Portfolio in the consumer eye care business and higher sales of SiHy Daily lenses and Ultra within the contact lens business. That was partially offset by unfilled orders due the a system upgrade at a Lynchburg distribution facility that impacted the lens business.
Revenue in the surgical segment was up 9% at $204 million, while revenue in the pharmaceuticals segment was up 67% to $307 million.
Operating income fell to $49 million from $51 million a year ago, mostly due to higher selling, general and administrative costs due to product launches.
The stock has fallen 21% in the last 12 months, while the S&P 500
SPX,
has gained 24.5%.
This story originally appeared on Marketwatch
